POIR.01.01.01-00-0021/16-00

POIR.01.01.01-00-0021/16-00
Between 2016 and 2022, NanoVelos Ltd. carried out a project co-financed by the European Funds titled “Preclinical and Clinical Studies of Innovative Nanoformulations of Anticancer Drugs.” The aim of the project was to develop an innovative nanoformulation of a selected, registered anticancer drug that would demonstrate reduced side effects and/or improved efficacy compared to the free (non-formulated) drug.
As part of the project, a formulation of dextran nanoparticles with epirubicin (POLEPI) was selected. The results of ex vivo and in vivo studies were published in two scientific papers (Int. J. Mol. Sci. 2024, 25(1), 645; Int. J. Mol. Sci. 2025, 26(3), 970), which describe the development and testing of the POLEPI product.
The company also obtained patent protection in China under patent number CN 112165933 B – “Anthracycline encapsulated with polysaccharide for use in the treatment of tumours.”

The invention concerns the use of a new form of the drug, in which an anthracycline is encapsulated with a polysaccharide for the treatment of specific cancers – in particular, when the polysaccharide used is dextran, the anthracycline is epirubicin, and the cancer is ovarian cancer.

Project value: PLN 5,237,116.64
Funding received: PLN 4,187,249.39